Literature DB >> 20094972

Aldosterone causes DNA strand breaks and chromosomal damage in renal cells, which are prevented by mineralocorticoid receptor antagonists.

N Schupp1, N Queisser, M Wolf, P Kolkhof, L Bärfacker, S Schäfer, A Heidland, H Stopper.   

Abstract

Epidemiological studies exploring the connection between hypertension and cancer incidence find a higher cancer mortality in hypertensive patients, particularly elevated in hypertension associated with a stimulation of the renin-angiotensin-aldosterone system. Primary aldosteronism, with plasma aldosterone levels between 0.5 and 1 nM (18-36 ng/dL) and local aldosterone levels up to 500 nM (18,000 ng/dL), is now recognised as a more common cause for hypertension. We recently found angiotensin II to be genotoxic due to its induction of oxidative stress. Since aldosterone in higher concentrations also has oxidative effects, its potential genotoxic action in pig LLC-PK1 cells with properties of proximal tubules was analysed. DNA damage was evaluated by two test systems: the comet assay, and the micronucleus frequency test. The results showed that aldosterone concentrations starting from 10 nM (360 ng/dL) caused a significant increase of DNA damage monitored with the comet assay in LLC-PK1, while there was no change in cell vitality and proliferation. The micronucleus frequency test revealed that 10 nM aldosterone also leads to the formation of micronuclei. Furthermore, the formation of superoxide radicals in the cells by this aldosterone concentration could be detected with the superoxide-specific stain dihydroethidium. Further evidence for oxidative stress-induced DNA damage was its reversibility by the antioxidants tempol and catalase. Addition of the steroidal mineralocorticoid receptor antagonist spironolactone or the novel selective nonsteroidal antagonist (R)-BR-4628 reduced the DNA damage and the amount of superoxide radicals indicating a receptor-dependent process. Georg Thieme Verlag KG Stuttgart-New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20094972     DOI: 10.1055/s-0029-1243253

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  8 in total

Review 1.  A comprehensive review of the clinical aspects of primary aldosteronism.

Authors:  Gian Paolo Rossi
Journal:  Nat Rev Endocrinol       Date:  2011-05-24       Impact factor: 43.330

Review 2.  Diagnosis and treatment of primary aldosteronism.

Authors:  Gian Paolo D Rossi
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

Review 3.  Prevalence and diagnosis of primary aldosteronism.

Authors:  Gian Paolo Rossi
Journal:  Curr Hypertens Rep       Date:  2010-10       Impact factor: 5.369

4.  Aldosterone activates transcription factor Nrf2 in kidney cells both in vitro and in vivo.

Authors:  Nina Queisser; Patricia I Oteiza; Samuel Link; Valentin Hey; Helga Stopper; Nicole Schupp
Journal:  Antioxid Redox Signal       Date:  2014-03-21       Impact factor: 8.401

5.  Oxidative DNA damage in kidneys and heart of hypertensive mice is prevented by blocking angiotensin II and aldosterone receptors.

Authors:  Susanne Brand; Kerstin Amann; Philipp Mandel; Anna Zimnol; Nicole Schupp
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

6.  Cardiac Dysfunction in Association with Increased Inflammatory Markers in Primary Aldosteronism.

Authors:  Jung Soo Lim; Sungha Park; Sung Il Park; Young Taik Oh; Eunhee Choi; Jang Young Kim; Yumie Rhee
Journal:  Endocrinol Metab (Seoul)       Date:  2016-11-03

7.  Evaluation of steroid hormones and their receptors in development and progression of renal cell carcinoma.

Authors:  Nigel C Bennett; Retnagowri Rajandram; Keng Lim Ng; Glenda C Gobe
Journal:  J Kidney Cancer VHL       Date:  2014-06-15

8.  Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation.

Authors:  Wai-Hang Leung; Queenie P Vong; Wenwei Lin; Laura Janke; Taosheng Chen; Wing Leung
Journal:  J Exp Med       Date:  2013-11-04       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.